SCHEMBL9890799

SCHEMBL9890799

O=C(Cc1ccccc1-c1ccccc1F)NCC1CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 2/20 0.45
CHRM2 P08172 1/20 0.45
CHRM4 P08173 1/20 0.45
CHRM5 P08912 1/20 0.45
CHRM3 P20309 1/20 0.45
KMT2A Q03164 1/20 0.44
PPIA P62937 2/20 0.43
VCP P55072 2/20 0.43
LMNA P02545 3/20 0.43
RAB9A P51151 2/20 0.43
HPGD P15428 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PIM1 P11309 1/20 0.41
PIM2 Q9P1W9 1/20 0.41
NPC1 O15118 2/20 0.41
SIGMAR1 Q99720 1/20 0.41
CCKBR P32239 1/20 0.41
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
ROCK2 O75116 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890798 0.81 SIGMAR1 (0.55) CHRM1CHRM3PPIALMNAHPGD
SCHEMBL22275812 0.81 ROCK2 (0.47) KMT2ALMNARAB9AHPGDSMN1; SMN2
SCHEMBL9890723 0.80 LMNA (0.47) KMT2APPIALMNARAB9AHPGD
SCHEMBL18191579 0.78 KMT2A (0.52) KMT2ASIGMAR1
SCHEMBL2395314 0.76 RAB9A (0.49) KMT2APPIALMNARAB9AHPGD
SCHEMBL20932663 0.74 NPC1 (0.56) KMT2ALMNARAB9AHPGDSMN1; SMN2
SCHEMBL9890784 0.72 ANO1 (0.47) KMT2APPIALMNARAB9AHPGD
SCHEMBL2409477 0.72 NPC1 (0.60) KMT2ALMNARAB9AHPGDNPC1
SCHEMBL20932709 0.72 IDO1 (0.44) KMT2ALMNARAB9AHPGDSMN1; SMN2
SCHEMBL21574289 0.72 KMT2A (0.54) KMT2ARAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CHRM1 340/4885CHRM2 159/4885CHRM4 1063/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CHRM1 340/4885CHRM2 159/4885CHRM4 1063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.